Efficacy and safety of male hormonal contraceptives
DOI:
https://doi.org/10.59471/ijhsc2025255Keywords:
Testosterone, Male Fertility, Male Hormonal Contraception, Family Planning, SpermatogenesisAbstract
Introduction: unwanted pregnancy accounts for almost half of all pregnancies worldwide. A wide variety of contraceptives are available for women, but not for men. Many men wish to take a more active role in family planning, but currently only two male contraceptive options are available: condoms and vasectomy. Male contraception began in the 18th century with the use of condoms and later in the 19th century with vasectomy. In recent years, there has been a delay in the research and development of male contraceptives, leaving men with few options.
Objectives: to describe the efficacy and safety of male hormonal contraceptives.
Methods: a search for information was conducted in the Pubmed database. Articles published between 2002 and 2024 in both English and Spanish were examined, clinical trials were selected and the results obtained in them were analyzed.
Results: a total of 60 publications were reviewed, of which 15 met the inclusion criteria. The populations studied were young, healthy men.
Conclusion: despite the limited variety of contraceptive methods available for men, science has made significant advances in the development of new hormonal methods. These advances promise, in the not so distant future, to offer safer, more effective and more accessible options for birth control for men
References
Gonzalo ITG, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, et al. Levonorgestrel implants (Norplant II) for male contraception clinical trials: Combination with transdermal and injectable testosterone. J Clin Endocrinol Metab. 2002. 87(8):3562–72. https://pubmed.ncbi.nlm.nih.gov/12161475/
Li J-W, Gu Y-Q. Predictors for partial suppression of spermatogenesis of hormonal male contraception. Asian J Androl. 2008;10(5):723–30. https://pubmed.ncbi.nlm.nih.gov/18645675/
Nguyen BT, Yuen F, Farrant M, Thirumalai A, Fernando F, Amory JK, et al. Acceptability of the oral hormonal male contraceptive prototype, 11β-methyl-19- nortestosterone dodecylcarbonate (11β-MNTDC), in a 28-day placebo-controlled trial. Contraception. 2021;104(5):531–7. https://pubmed.ncbi.nlm.nih.gov/34153318/
Roth MY, Shih G, Ilani N, Wang C, Page ST, Bremner WJ, et al. Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial. Contraception. 2014;90(4):407–12. https://pubmed.ncbi.nlm.nih.gov/24981149/
Anawalt BD, Amory JK, Herbst KL, Coviello AD, Page ST, Bremner WJ, et al. Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: A randomized clinical trial. J Androl. 2005;26(3):405–13. https://pubmed.ncbi.nlm.nih.gov/15867009/
Qoubaitary A, Meriggiola C, Ng CM, Lumbreras L, Cerpolini S, Pelusi G, et al. Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. J Androl. 2006;27(6):853–67. https://pubmed.ncbi.nlm.nih.gov/16837736/
Mahabadi V, Amory JK, Swerdloff RS, Bremner WJ, Page ST, Sitruk-Ware R, et al. Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men. J Clin Endocrinol Metab. 2009;94(7):2313–20. https://pubmed.ncbi.nlm.nih.gov/19366848/
Ayoub R, Page ST, Swerdloff RS, Liu PY, Amory JK, Leung A, et al. Comparison of the single dose pharmacokinetics, pharmacodynamics, and safety of two novel oral formulations of dimethandrolone undecanoate (DMAU): a potential oral, male contraceptive. Andrology. 2017;5(2):278–85. https://pubmed.ncbi.nlm.nih.gov/27907978/
Yuen F, Thirumalai A, Pham C, Swerdloff RS, Anawalt BD, Liu PY, et al. Daily oral administration of the novel androgen 11β-MNTDC markedly suppresses serum gonadotropins in healthy men. J Clin Endocrinol Metab. 2020;105(3):e835–47. https://pubmed.ncbi.nlm.nih.gov/31976519/
Wu S, Yuen F, Swerdloff RS, Pak Y, Thirumalai A, Liu PY, et al. Safety and pharmacokinetics of single-dose novel oral androgen 11β-methyl-19- nortestosterone-17β- dodecylcarbonate in men. J Clin Endocrinol Metab. 2019;104(3):629–38. https://pubmed.ncbi.nlm.nih.gov/30252057/
Surampudi P, Page ST, Swerdloff RS, Nya-Ngatchou JJ, Liu PY, Amory JK, et al. Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive. Andrology. 2014; 2(4):579–87. https://pubmed.ncbi.nlm.nih.gov/24789057
Nguyen BT, Farrant MT, Anawalt BD, Yuen F, Thirumalai A, Amory JK, et al. Acceptability of oral dimethandrolone undecanoate in a 28-day placebo- controlled trial of a hormonal male contraceptive prototype. Contraception. 2020;102(1):52–7. https://pubmed.ncbi.nlm.nih.gov/32298717/
Anawalt BD, Roth MY, Ceponis J, Surampudi V, Amory JK, Swerdloff RS, et al. Combined nestorone– testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men. Andrology. 2019;7(6):878–87. https://pubmed.ncbi.nlm.nih.gov/30969032/
Amory JK, Kalhorn TF, Page ST. Pharmacokinetics and pharmacodynamics of oral testosterone enanthate plus dutasteride for 4 weeks in normal men: Implications for male hormonal contraception. J Androl. 2008; 29(3):260–71. https://pubmed.ncbi.nlm.nih.gov/18046048/
Ilani N, Roth MY, Amory JK, Swerdloff RS, Dart C, Page ST, et al. A new combination of testosterone and nestorone transdermal gels for male hormonal contraception. J Clin Endocrinol Metab. 2012;97(10):3476–86. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22791756/
Suryani Arifin E, Mulawardhana P, Wardhani P. Comparison of Detection of HPV DNA from Menstrual Blood in Menstrual Cup and Cervical Swab in Sexual Single Partner and Multi-Partner Women. Salud, Ciencia y Tecnología. 2024; 4:1291. https://doi.org/10.56294/saludcyt20241291
Rivera Miranda Y, Sánchez Oropesa Y, Miranda Cordero L, Pérez Rilova D, Martínez Alonso I. Human papillomavirus educational intervention strategy for women of childbearing age. Salud, Ciencia y Tecnología - Serie de Conferencias. 2022; 1:278. https://doi.org/10.56294/sctconf2022278
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Claudia Daiana Maciel, Analia Claudia Sabattini (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
How to Cite
